Actively Recruiting
Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy
Led by Ain Shams University · Updated on 2024-07-16
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the intermediate-term effects of adding Captopril, a medication, on heart function in patients with Duchenne myodystrophy (DMD). This study focuses on how Captopril may impact the left ventricle's function as measured by a specific heart imaging technique called Global Longitudinal Strain (GLS). Duchenne myodystrophy is a genetic condition that affects the heart muscle, and this trial aims to understand if Captopril can influence the progression of related heart issues. Participants with Duchenne myodystrophy will be given Captopril tablets as an add-on therapy. The study does not involve a placebo or comparison group, and it is an early-phase interventional trial. The treatment period and specific dosing schedules are not detailed, but the focus is on measuring changes in heart function over time while on Captopril. During the study, participants will undergo heart imaging to measure the Global Longitudinal Strain, which helps assess the left ventricle's function. Researchers will track changes in GLS over six months to observe the effects of Captopril on heart muscle performance. Safety and tolerability will also be monitored, with the entire participation lasting at least six months to evaluate the intermediate-term impact of the treatment.
CONDITIONS
Brief Title
Effect of Captopril on GLS in Duchenne Myodystrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal Global Longitudinal Strain less than -18%
- Male patients
- Minimum age of 6 years old
You will not qualify if you...
- Patient refusal to sign informed consent
- Contraindications to ACE inhibitors, including hypersensitivity, kidney problems, bilateral renal artery stenosis, aortic valve stenosis, high potassium levels, or low blood pressure
- Heart ejection fraction below 50%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants take captopril tablets to assess the effect on left ventricular function measured by global longitudinal strain.
Visits at baseline and periodic assessments during treatment
Trial Site Locations
Total: 1 location
1
Ain Shams university
Cairo, Egypt
Actively Recruiting
Research Team
F
Fatma Ebeid, MD
S
Sandra M Mina
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here